Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 4Stomach Neoplasms 1Rare Tumour 1Neoplasms 1Neoadjuvant Therapy 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Locally Advanced Prostate Cancer 1Limited Stage Small Cell Lung Cancer 1Hereditary leiomyomatosis and renal cell cancer 1HER2-negative Breast Cancer 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

durvalumab 2Etoposide 2Cisplatin 2tislelizumab 1pamiparib 1anlotinib 1Tirapazamine 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Probiotics 1Immunotherapy 1Drug Therapy 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Limited Stage Small Cell Lung Cancer × pamiparib × Clear all
NCT05483543 2022-08-02

Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy

Fudan University

Phase 2 Unknown
44 enrolled
Thoracic

Limited Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡